What are the targets of lorlatinib? Mainly focusing on ALK and ROS1 gene mutation analysis

Lorlatinib (Lolatinib) is a third-generation ALK (anaplastic lymphoma kinase) inhibitor and an important targeted therapy for ROS1 gene fusion-positive tumors. As a small molecule tyrosine kinase inhibitor (TKI), lorlatinib (lorlatinib) is specially designed to deal with resistance mutations that emerge after treatment failure of previous generation ALK inhibitors (such as crizotinib, ceritinib, and alectinib), so it has a broader coverage of mutation targets. It has a strong inhibitory effect on multiple drug-resistant mutation sites of the ALK gene, especially the common G1202R mutation, which is a "refractory" drug-resistant mutation.

The main target of lorlatinib is ALK fusion gene mutation, which is especially suitable for ALK positive patients in non-small cell lung cancer (NSCLC). The ALK gene usually forms an oncogenic driver gene after fusion with EML4 and other genes, leading to abnormal proliferation of tumor cells. Lorlatinib (lorlatinib) can potently inhibit the activity of this fusion protein kinase and can penetrate the blood-brain barrier, giving it unique advantages in controlling brain metastasis. Compared with the first and second generation ALK inhibitors, lorlatinib has a wider spectrum of action. It is not only effective against the initial mutation, but also active against multiple drug-resistant mutations that occurred after previous treatment.

In addition to ALKfusion, lorlatinib (lorlatinib) is also designed to be used in patients with non-small cell lung cancer who are ROS1 gene fusion positive. ROS1 and ALK belong to the same tyrosine kinase family, and their fusion mutations can also lead to abnormal cell signaling and tumor growth. Lorlatinib (lorlatinib) has inhibitory activity against ROS1 fusion protein, especially in patients who are resistant to drugs such as crizotinib, and may still exert anti-tumor effects. However, it should be noted that there are fewer studies on lorlatinib (lorlatinib) in the treatment of ROS1 mutations than ALK, so its use should be combined with specific clinical conditions and genetic testing results.

In general, lorlatinib is a highly selective, highly penetrating drug that covers multiple mutation sitesALK/ROS1Dual-targeted inhibitor is suitable for patients with advanced non-small cell lung cancer who have failed previous treatment or have brain metastasis. Its clear target mechanism of action makes it of great value in personalized precision therapy, but genetic testing is still required before use to confirm the ALK or ROS1 fusion status to ensure the efficacy and safety of the drug.

Reference link:https://www.lorbrena.com/